Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Golodirsen in DMD
NCT02310906Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Jan 2015
- Primary completion
- Mar 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 4
01
Overview
A Phase 2 trial of golodirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Jan 2015; status: completed.
02
Drugs
golodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02310906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310906.